Meyne, Johannes
Domschikowski, Mirjam
Hensler, Johannes
Helmers, Ann-Kristin
Berg, Daniela
Deuschl, Günther
Paschen, Steffen http://orcid.org/0000-0002-9306-8332
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Article History
Received: 28 March 2023
Revised: 2 May 2023
Accepted: 3 May 2023
First Online: 22 May 2023
Declarations
:
: Dr. Meyne reports no conflicts of interest. Dr. Domschikowski reports no conflicts of interest. Dr. Hensler reports no conflicts of interest. Dr. Helmers reports no conflicts of interest. Dr. Berg received consultancies/advisory board fees for Biogen, BIAL, UCB Pharma GmbH, Zambon, honoraria for talks/lectures from AbbVie, Bayser, Biogen, BIAL, UCB Pharma GmbH, Zambon, and Desitin and grants/research funding from Deutsche Forschungsgemeinschaft (DFG), German Parkinson’s Disease Association (dPV), BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, and the Damp Foundation. Dr. Deuschl received fees for lecturing from Boston Scientific and consulting fees from Boston Scientific, Cavion, Functional modulation. He receives funding for his research to his institution from the German Research Council, SFB 1261, B5, and Medtronic. Dr. Paschen reports speaker honoraria from Insightec, AbbVie, Medtronic GmbH and Boston Scientific outside the submitted work and travel grants from Desitin and Abbvie and grant/research funding from Parkinson Fonds Deuschland gGmbH and UCB Pharma GmbH.
: The study was approved by the local ethics committee (D497/22). Based on the ethics committee decision, informed consent was not obtained.
: This study provides class IV evidence that IVT and MT may be applied in patients with DBS and ischemic stroke based on an individual risk-benefit analysis, taking into account the time between previous DBS surgery and IVT and/or MT.”